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The Rho GTPases organize the actin cytoskeleton and are involved in cancer metastasis. Previously, we demonstrated that RhoC
GTPase was required for PC-3 prostate cancer cell invasion. Targeted down-regulation of RhoC led to sustained activation of
Rac1 GTPase and morphological,molecular andphenotypic changes reminiscent of epithelial to mesenchymal transition. We also
reported that Rac1 is required forPC-3 cell diapedesis across a bone marrowendothelial cell layer. In the current study, we queried
whether Rac3 and RhoG GTPases also have a role in prostate tumor cell diapedesis. Using speciﬁc siRNAs we demonstrate roles
for each protein in PC-3 and C4-2 cell adhesion and diapedesis. We have shown that the chemokine CCL2 induces tumor cell
diapedesis via Rac1 activation. Here we ﬁnd that RhoG partially contributes to CCL2-induced tumor cell diapedesis. We also ﬁnd
that Rac1 GTPase mediates tight binding of prostate cancer cells to bone marrow endothelial cells and promotes retraction of
endothelial cells required for tumorcell diapedesis. Finally, Rac1 leads to β1 integrin activation, suggestinga mechanismthat Rac1
can mediate tight binding with endothelial cells. Together, our data suggest that Rac1 GTPase is key mediator of prostate cancer
cell-bone marrow endothelial cell interactions.
1.Introduction
Skeletal metastases represent a major clinical problem for
men suﬀering from prostate cancer (PCa). Nearly 80% of
men who die from this disease have signiﬁcant spread of
t h ec a n c e rt ob o n e[ 1, 2]. Like all cancers, PCa cells must
successfully complete a series of ordered steps, known as
the metastatic cascade, to form a distant tumor [3, 4]. One
key step in the PCa metastatic cascade is the process of
extravasation from the circulation into the bone microen-
vironment [5, 6]. The process of PCa cell extravasation can
be subdivided into a number of substeps, which include
arrest, binding, adhesion, and spreading on bone marrow
endothelial cells, migration along the endothelial barrier,
tumor cell diapedesis, and invasion into the bone stromal
compartment [6–8]. Although many of these substeps have
been well studied for leukocyte extravasation, relatively little
is known about the process of PCa tumor cell extravasation
across a bone marrow endothelium (reviewed in [9]).
The Rho GTPases are a group of proteins that comprise
a subfamily of the Ras-superfamily of monomeric GTP-
binding proteins that act as molecular switches regulating
the cytoskeleton promoting cell migration [10–14]. Further-
more, the Rho proteins are implicated in cancer progression
and metastasis (reviewed in [15]). Previously, we have
suggested potential roles for individual Rho GTPases in
PCa extravasation [16–18]. Speciﬁcally, we demonstrated
that RhoC GTPase is required for invasion in response to
insulin-like growth factor I and type I collagen [16, 18].
Upregulation of the integrin heterodimer α2β1i nL N C a P
cells selected for their ability to bind to type I collagen led
to increased RhoC activation and cellular invasion upon2 Journal of Signal Transduction
integrin ligation [19, 20]. Downregulation of RhoC in
PC-3 human PCa cells through introduction of either a
dominant negative (dn)RhoC or a RhoC-speciﬁc shRNA
led to a signiﬁcant decrease in the cells ability to invade
either collagen or Matrigel-coated ﬁlters [16, 18]. However,
these cells underwent changes reminiscent of epithelial to
mesenchymal transition (EMT). Concordant with EMT,
the cells displayed increased random linear motility, which
was due to increased and sustained levels of Rac1 GTPase
expression and activation. Further, we demonstrated that
activeRac1GTPase isrequiredforPC-3celldiapedesisacross
aB M E Cl a y e r[ 18].
The Rac GTPase branch of the Rho subfamily is com-
prised of four members, Rac1, Rac2, Rac3, and RhoG. Rac1
and RhoG are ubiquitously expressed, while Rac2 is primar-
ily expressed in hematopoietic cells, and Rac3 is expressed
mainly in nervous tissue but can be found expressed at
lower levelsin most other tissues (reviewed in [21]). Seminal
experiments demonstrated a role for Rac1 in the formation
of lamellipodia [11, 13, 14, 22, 23]. Recent evidence suggests
a role for Rac3 GTPase in cellular adhesion and neurite
outgrowth [24–26]. RhoG GTPase has been shown to signal
in a parallel pathway to Rac1, being regulated by some of
the same upstream regulatory proteins such as Vav2 and
activating some of the same downstream eﬀectors as Rac1
[27]. RhoG has also been shown to act as a hierarchical
GTPase; activationofRhoGcanleadtotheactivationofRac1
through direct interaction with the Dock180-ELMO [28].
Therefore, Rac1-mediated cell migration can be regulated
through direct activation of RacGEFs or via RhoG GTPase
[29].
Rac1 GTPase plays an intimate role in monocyte and
macrophage diapedesis [30]. Monocytes are recruited to the
sites of inﬂammation via stimulation by the chemokine
CCL2 (a.k.a. MCP-1) [31]. Binding of CCL2 to its puta-
tive receptor CCR2 leads to clustering of the novel actin
regulatory protein PCNT1 to the cells leading edge and
regulation of migration through activation of Rac1 [30].
Activation of Rac1 is required to form lamellipodia, which
in turn is required for monocytes to sense junctions between
endothelialcells [30].BMECs from PCapatientssecrete high
levels of CCL2 [32]. Stimulation of PC-3 cells with CCL2
results in activation of Rac1 GTPase and EMT consistent
with what is observed when RhoC activity is downregulated
through introduction of a dnRhoC or shRNA to RhoC [16–
18]. Furthermore, CCL2 stimulation drives PC-3 tumor cell
diapedesis across a BMEC layer via PCNT1 [17].
Levels of Rac1 and Rac3, but not Rac2, are shown to
be increased in prostate cancer patient samples compared to
normal prostate [33]. However, the role that these GTPases
play in PCa tumor cell metastasis has not been thoroughly
studied. Similarly, there is no information on the contribu-
tion of RhoG to PCa progression. In the current study we
investigate the roles of Rac1, Rac3, and RhoG GTPases in
the process of prostate tumor cell diapedesis across a bone
marrow endothelial cell layer. All three Rac proteins have an
inﬂuence on tumor cell diapedesis across a bone marrow
endothelial cell monolayer. Further, we demonstrate that
Rac1 GTPase has a signiﬁcant eﬀect on PCa cell diapedesis,
while Rac3 has a negative eﬀect on tumor cell diapedesis.
In addition, RhoG has a partial eﬀect on CCL2-stimulated
diapedesis. Finally, Rac1 regulates binding of prostate cancer
cells to the bone marrow endothelial cells. Our data suggest
thatRac1isrequiredfortheactivationofβ1integrins leading
tobinding ofthe prostate cancercelltothe BMEC.This isthe
ﬁrst study to demonstrate roles for diﬀerent isoforms of Rac
GTPase in the PCa metastatic phenotype.
2.Materialsand Methods
2.1. Cell Lines and Cell Culture. PC-3 PCa cell lines were
obtained from American Type Culture Collection (Man-
assas, Va) and maintained in Ham’s F-12 medium with
1.5g/L sodium pyruvate, 2mM L-glutamine, and 10%
FBS (Invitrogen/Gibco, Carlsbad, Calif). C4-2 cells were a
gift from Dr. Robert Sikes (University of Delaware) and
maintained in T-medium containing 10% FBS (Invitro-
gen/Gibco).Humanbonemarrow endothelialcells(BMECs)
were a gift from Dr. Graca Almeida-Porada (University of
Nevada School of Medicine, Reno, Nevada). Cultures were
maintained in Medium 199 with Earles’s salts, L-glutamine,
2,200mg/L sodium bicarbonate, 25mM HEPES (Invitro-
gen/Gibco) buﬀer, 10% FBS, 1% pen/strep, endothelial
cell growth supplement (BD Biosciences, Bedford, Mass),
and 7500u/500mL media of heparin (Sigma-Aldrich, St.
Louis, Mo). All cell lines were maintained at 37◦Ci n
a 90%:10% air:CO2 incubator. C3 exotransferase was
introduced into cells as previously described using a lipid
transfer-mediated method [34]a n dt r e a t e df o r2 hb e f o r e
analysis. Rac1 inhibitor NSC23766 (Calbiochem, San Diego,
Calif) treatment was performed by adding directly to tissue
culture medium to a ﬁnal concentration of 100μM1 h
prior to analysis. Prostate cancer cells were stimulated with
100ng/mLrecombinant human(rh)CCL2(MCP-1)intissue
culture medium (Millipore-Chemicon Inc., Billeceria, Mass)
for 30min during the Rac activation assays and kept in the
presence of the chemokines during the diapedesis assays.
2.2. siRNAs. Speciﬁc siRNAs for human Rac1 and Rac3
GTPases were a gift from Dr. Marc Symons and described
previously [26]. RhoG siRNA and scrambled control siRNAs
were synthesized by integrated DNA technologies. RhoG
siRNA target sequences were (1) 5 -TGCCCTGATGTG-
CCCATCCTGCTGGTGGG-3  and (2) 5 -ACGTGCCTG-
CTCATCTGCTACACAACTAA-3 .T h eR a c 1 ,R a c 3 ,a n d
RhoG siRNA duplexes were formed by adding 30μLo fe a c h
RNA oligo solution together with 15μL of 5x annealing
buﬀer (100mM NaCland 50mM Tris-HCl pH 7.5) to give
a ﬁnal volume of 75μL and a ﬁnal concentration of 20μM;
incubated for 2min in water bath at 95◦C; allowed to cool to
room temperature. Additional experiments were performed
using ON-TARGET plus SMARTpool siRNAs Rac1, Rac3,
and RhoG siRNAs that were obtained from Dharmacon
(Dharmacon/Thermo Scientiﬁc, Layfette, Colo). siRNAs
were transfected into prostate cancer cells using FuGene6
(Roche, Indianapolis, Ind) or GeneSilencer Reagent (Gen-
lantis, San Diego, Calif) per the manufacturers instructionsJournal of Signal Transduction 3
andcellsused72haftertransfection. Forrescueexperiments,
mutations were generated using the QuickChange II Site-
Directed Mutagenesis kit (Stratagene) according to the
manufactures recommendations. To fully abolish the eﬀect
of siRNAs, two nucleotides in the siRNA-targeted area were
changed in both Rac3 and RhoG GTPases. To create a RhoG
fast cycling mutant, glutamine 63 was converted to lysine.
2.3. Reverse Transcriptase and Real-Time Quantitative PCR.
Total RNA was harvested from cells and converted to cDNA
as previously described [16]. PCR primers were designed
using the primer design feature on the Evocycler PCR
program (Evogen Ltd., UK). Primer design parameters were
set to optimally produce PCR products between 100 and
150bp in size. Primer sequences are found in Supplemental
Table 1 (see Table 1 in Supplementary Material available
online at doi:10.1155/2011/541851).RT-PCR wasperformed
on an Evocycler EPx (Evogen Ltd.) using Fast SYBR Green
chemistry (Applied Biosystems Inc., Foster City, Calif) per
the manufacturers recommendations for 30 cycles (98◦C
for 15s, 67◦Cf o r1 5 s ,a n d7 2 ◦Cf o r3 0 s ) ,a n dP C R
productsvisualized on a virtual gel and band intensities were
normalized to GAPDH using the Evocycler PCR program.
For quantitative (q)PCR, RNA was isolated from the
cell lines using TRIzol Reagent (Invitrogen, Carlsbad, Calif).
cDNA was synthesized from this RNA using the Promega
Reverse Transcription kit (Promega Corp., Madison, Wis).
Appropriate primers (Integrated DNA Technologies, Inc.,
Coralville, Iowa) were diluted to a ﬁnal concentration of
10μM. The cDNA synthesized from the isolated RNA was
diluted to a ﬁnal concentration of 4ng/μL. Reactions were
prepared as a bulk “master mix” using the ABI SYBR Green
PCRMaster Mix(AppliedBiosystems Inc.,FosterCity,Calif)
for each target gene/primer pair used. Three no-template
controls were included for each primer pair being used. A
5μL aliquot of cDNA was pipetted into each well of the
ABI 96-well plate, and 20μL of the reaction master mix was
added to it. Plates were covered with ABI adhesive cover,
centrifuged at 1000rpm to mix the contents, and run on an
ABI 7000 real-time qPCR machine housed in the Center for
Translational Cancer Research (University of Delaware).
2.4. Tumor Cell Diapedesis Assays. Tumor cell diapedesis
assays were performed as previously described [18]. Brieﬂy,
100,000 HBME cells were added to the top chamber of
either uncoated or Matrigel-coated Transwells 24h prior
to the assay and allowed to form a conﬂuent monolayer.
PC-3 and C4-2 cells were harvested, labeled with Calcein
AM (Invitrogen/Molecular Probes) per manufacturers rec-
ommendations, and resuspended in serum-free medium
containing 0.1% BSA at a concentration of 3.75 × 105
cells/mL, and 0.5mL was added to the top chambers. The
chambers were incubated for 24h at 37◦C in a 10% CO2
incubator. Medium was aspirated from the top chamber,
and excess Matrigel and cells were removed from the
ﬁlter using a cotton swab. Filters were cut away from the
inserts, mounted on microscope slides, and visualized on a
ﬂuorescentmicroscopeandnumberofinvadedcellscounted.
2.5. Rac GTPase Activation Assay. Activation of total Rac
GTPase proteins was performed using a GLISA pan-Rac
activation assay kit (Cytoskeleton Inc., Denver, Colo) as
previously described [18]. Brieﬂy, prostate cancer cells were
grown to 75% conﬂuence in a 100mm dishes and serum
starved for 24h. On the day of the assay, cells were harvested
usingnonenzymaticcelldissociationbuﬀer(Sigma-Aldrich),
washed twice with ice-cold PBS, and resuspended in 65μL
GLISA lysis buﬀer. Protein lysates were transferred to ice-
cold 1.5mL centrifuge tubes and clariﬁed by centrifugation
at 10,000rpm for 2min. Protein concentrations were deter-
mined using the supplied Precision Red advance protein
assay and 1.0mg/mL protein used for the GTPase activation
assay per manufacturers recommendations. After antibody
and horseradish peroxidase detection reagent incubation,
signals were detected on a Benchmark Plus microplate spec-
trophotometer at 490nm (Bio-Rad Laboratories, Hercules,
Calif).
2.6. Atomic Force Microscopy. All AFM experiments were
conducted with a Bioscope II (Vecco, Santa Barbara,
Calif) using silicon-nitride tips (Vecco; spring constant
0.06N/m). Unbinding force measurements were conducted
with tips functionalized with collagen or ﬁbronectin
(Becton-Dickinson, Franklin Lakes, NJ) at concentrations of
50μg/mL and 15μg/mL, respectively. Likewise, 35mm tissue
culture dishes (Corning Inc., Corning, NY) were coated with
collagen or ﬁbronectin and sterilized under ultraviolet light
overnight. PC-3 cells were transfected with siRNA speciﬁc
for Rac1, Rac3, or RhoG using FuGene6 (Roche) or GeneSi-
lencerReagent(Genlantis) and platedon the prepared dishes
8h priorto experimentation. BMECswere cultured in RPMI
1640media (Hyclone/ThermoScientiﬁc)supplementedwith
10% FBS. The functionalized AFM tip was dropped onto
a single live BMEC cell and after attachment was veriﬁed,
the loaded tip was gently lowered onto the center of a PC-
3 cell. The unbinding force interaction between the two
live cells was measured. The unbinding force is the force
requiredtoseparatetwoadhesionmoleculesand ismeasured
in picoNewtons (pN). The number of events for a particular
unbindingforceisthenumberofmoleculesseparatedateach
force. Speciﬁcally, 250 unbinding events were captured per
cell site with 4 areas probed per cell, and 3 separate cells
were probed per treatment. Force curves were generated at
a frequency of 1Hz in a relative trigger mode.
AFM stiﬀness measurements were based on recording
the elastic response of cells, BMECs and PC-3s using an
AFM tip. The AFM was operated in the force-volume mode
for recording a set of loading/unloading load displacement
curves at a frequency of 1.03Hz and a forward/reverse
velocity of 4.11μm/sec. The resultant measurement is the
dynamicelasticmodulus(a.k.a.theYoung’smodulus),which
measures the stiﬀness of the cell. The Young’s modulus is
the ratio of stress to strain and is thus represented by units
of pressure, Pascals (Pa). Cell stiﬀness changes are due to
morphologic changes resulting from alterations in cytoskele-
tal structure (reviewed in [35]). The elastic modulus was
measured with individual BMECs, individual PC-3 cells, and4 Journal of Signal Transduction
the duo: PC-3 cells attached to plated BMECs and BMECs
attached to plated PC-3 cells. The elastic modulus for the
BMEC/PC-3 combinations was generated for the plated cell,
and the attached cells separately. Each force-volume map
consists of 256 data points per sample site with 3 separate
sites measured per experimental condition, 3 separate times.
2.7. Transendothelial Electrical Resistance (TEER). Transen-
dothelial electrical resistance (TEER) measurements were
done using Epithelial Voltohmmeter (EVOM; World Preci-
sion Instruments Inc., Sarasota, Fla) following manufactur-
ers directions. Brieﬂy, BMECs were plated at a concentra-
tion of 1.3 × 106 cells/mL on 12-well 0.4μ polycarbonate
membrane inserts (CLS3401; Corning Transwell) and were
maintained until day 4 (we determined empirically that the
TEER for the BMEC monolayer was optimum on day 4 after
plating due to maturation of cell junctions). On day 4, tissue
culture medium was removed from the top chamber, an
equal concentration of PC-3 cells was added to the BMEC
monolayer and TEER measured at speciﬁed intervals.
2.8. Fluorescence-Activated Cell Sorting (FACS) Analysis.
Prostate cancer cells were cultured in T25 ﬂasks (Corning
Inc., Edison, NJ), detached, washed, and resuspended in 5%
bovine serum albumin (BSA; Sigma-Aldrich) in phosphate
buﬀered saline (PBS; Sigma-Aldrich). All washes and resus-
pensions were also performed in 5% BSA containing PBS.
One set of control and siRac1-transfected prostate cancer
cells were each further treated with CCL2 (100ng/mL)
for 30min, washed, and resuspended. The several states
of β1 activation were queried with two conformation-
sensitive antibodies N29 (BD Biosciences, Franklin Lakes,
NJ) and HUTS-21 (BD Biosciences) in addition toa total
β1 conformation-insensitive antibody, MAR4 (Chemicon,
Billerica, Mass). All antibodies were used at a ﬁnal concen-
tration of 10μg/mL, and all incubations were conducted in
the dark and at 37◦C. Cells were analyzed using an FACS
Calibur cytometer (BD Biosciences), equipped with 488nm
and 633nm lasers. Analyses were performed on10,000-gated
events, and the numeric data were processed with Cellquest
software (Becton Dickinson).
2.9. Statistical Analysis. All experiments were performed a
minimum of three separate times with individual trans-
fections consisting of no less than three replicates per
experiment. Statistical analysis of the combine experiments
was performed using GraphPad Prism and by the University
of Delaware College of Agriculture and Natural Resources
Statistics Laboratory. A one-way ANOVA analysis was used
with Bonferroni’s post hoc analysis for comparison between
multiple groups. A Students t-test was used for comparison
between two groups. Signiﬁcance was deﬁned as a P value <
.001. Data is represented as mean ± standard deviation.
3.Results
3.1. Active Rac GTPases Aﬀect Prostate Cancer Cell Transen-
dothelial Migration. Previously, we demonstrated that Rac1
GTPase was required for tumor cell transendothelial cell
migration. However, we did not thoroughly explore if other
Rac family members contributed to diapedesis [16–18]. The
expression of Rac1 and Rac3 GTPases is increased in PCa
patient tumors; however, it is unknown if RhoG is expressed
[33]. Using quantitative (q)PCR, we demonstrate detectable
message for Rac1, Rac3 and RhoG in the PC-3 cells. As
shown in Figure 1(a), normalized Rac1 mRNA expression
levels were on average 8-fold higher than both Rac3, and
RhoG, suggesting that Rac1 is the predominant Rac GTPase
expressed in the PC-3 cells. Expression levelswere conﬁrmed
when theproductsofasemiquantitative PCRwere visualized
by virtual gel (Supplemental Figure 1). Band intensity for
each product on the virtual gel is automatically normalized
to the corresponding GAPDH.Similar expression levelswere
observed forC4-2 prostate cancercells (SupplementalFigure
2(a)). Due to the lack of speciﬁc antibodies, particularly for
Rac3, protein expression levels were not assessed by Western
blot analysis.
Toelucidatetheroleofeach Racproteinintransendothe-
lial cell migration, we selectively downregulated the expres-
sion of Rac GTPase isoforms using siRNA. Figure 1(a)
is the results of isoform-speciﬁc Rac message depletion
using siRNA duplexes. Expression of each Rac mRNA was
signiﬁcantly reduced by a minimum of 80% compared to
PC-3 cells treated with an appropriate scrambled control.
Each siRNA speciﬁcally reduced its target without aﬀecting
o t h e rR a cG T P a s e so ra ﬀecting cell growth (growth data
not shown). Similar results were seen when alternate siRNAs
were used for each Rac isoform.
PC-3 cells were treated with the pharmacologic RacGEF
inhibitor NSC23766 (iRac) or Rac-speciﬁc siRNA and the
eﬀect on total Rac activity determined (Figure 1(b)). As
expected, both the NSC23766 inhibitor and Rac1-speciﬁc
siRNA reduced total active Rac levels by ∼60% compared to
untransfected control.Interestingly, knockdownofRhoGled
to asigniﬁcant 45%reduction in totalRacactivity suggesting
thatRhoGmayactivateRac1duringphysiologicprocesssuch
as diapedesis. In contrast to Rac1 and RhoG, knockdown
of Rac3 resulted in a signiﬁcant 52% increase in total Rac
activity compared to control.
Since Rac GTPases are required for transendothelial cell
migration across a BMEC layer [18], we next tested the
individual role of Rac1, Rac3, and RhoG in PCa diapedesis
across a BMEC layer. As expected, downregulation of Rac1
led to a signiﬁcant decrease in diapedesis (Figure 1(c)).
However, inhibition of RhoG and Rac3 had no eﬀect
on inhibiting tumor cell diapedesis. In contrast to Rac1,
depletion of Rac3 led to a 70% increase in transendothe-
lial migration, suggesting that Rac3 limits PCa diapedesis
similar to what has been shown for RhoA in PCa invasion
[18]. The increase in diapedesis observed when RhoG was
depleted approached but did not achieve signiﬁcance com-
pared to untransfected or scrambled controls. Figure 1(d)
demonstrates that expression of a siRNA-resistant Rac3 in
Rac3-downregulated cells results in a signiﬁcant decrease
in diapedesis. Similarly, re-expression of RhoG led to a
signiﬁcant decrease in diapedesis compared to cells depleted
of RhoG. This suggests a negative eﬀect of Rac3 and possiblyJournal of Signal Transduction 5
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Figure 1: Eﬀect of Rac depletion on total Rac activation and tumor cell diapedesis across a bone marrow endothelial cell monolayer.
(a) Rac isoform expression and isoform-speciﬁc depletion in PC-3 cells. Individual siRNAs (1) and (2), speciﬁc for Rac1, Rac3, or RhoG,
were compared. Messenger RNA was harvested and SYBR green-based qPCR performed using primers speciﬁed in Supplemental Table 1.
Relative expression levels were normalized to GAPDH expression from the corresponding sample and expressed as arbitrary units (a.u.).
(b) is the eﬀect of the RacGEF inhibitor NSC23766 (iRac), siRNA speciﬁc for Rac1, Rac3, and RhoG, or scrambled control (siScr) on
total Rac activation. Cells were treated with 100μM NSC23766 for 1h or 20μM siRac1, siRac3, or siRhoG. Activation of total Rac was
performed using GLISA. Cells treated with iRac or transfected with siRNA to Rac isoforms were compared with untransfected (UT) and
representative siRNA-scrambled control (siScr). Each analysis was performed in triplicate with individual transfections. (c) BMECs were
layered onto a Matrigel-coated ﬁlter and allowed to form a monolayer;0.5mL ofa suspensionof 3.75×10
5 PC-3 cells/mL were added to the
BMECs and allowed to undergo diapedesis for 24h. Treated and transfected cells were compared with untransfected or scrambled controls.
(d) Introduction of an RNAi-insensitive Rac3 into siRac3-treated PC-3 cell. Shown in all four panels is the mean ± S.D. of at least triplicate
analysis with signiﬁcance being ∗P<. 001. Noncapped lines above the bars represent that the siRNA group is signiﬁcantly diﬀerent from
controls.
RhoG on tumor cell diapedesis. Supplemental Figure 2(b)
demonstrates a similar trend for the C4-2 prostate cancer
cells. Depletion of Rac1 led to a signiﬁcant decrease in
transendothelial cell migration. However, depletion of Rac3
or RhoG increased tumor cell diapedesis. Rescue exper-
iments reversed the trends of the siRNAs in the C4-2
cells.
3.2. The Chemokine CCL2 Stimulates Diapedesis via RhoG
GTPase. The chemokine CCL2 is produced by BMECs and
stimulates Rac1-mediated tumor cell diapedesis [17, 32].
S i n c eR h o Ga p p e a r st oh a v ea ne ﬀect on Rac activa-
tion, we next set out to determine if CCL2-stimulated dia-
pedesis could be aﬀected by depletion of RhoG. As shown in
Figure 2(a), CCL2 treatment increased diapedesis 3-fold6 Journal of Signal Transduction
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Figure 2: Eﬀect of Rac depletion on tumor cell diapedesis across a BMEC monolayer. (a) PC-3 cells were treated with 100ng/mL CCL2
in a diapedesis assay. Control untransfected (UT) and siRNA control (siScr) cells demonstrated increased diapedesis compared with
untreated/untransfected (UN/UT) PC-3 cells. The ability of cells to undergo CCL2-stimulated diapedesis after depletion of Rac1, RhoG,
or treatment with iRac was compared to UT and siScr. Rescue experiments of RhoG-depleted cells were performed by the introduction
of a siRNA-insensitive RhoG. Rac1-depleted cells were rescued with the introduction of fast cycling RhoG (RhoGQ63L). (b) Depletion
of RhoG led to a decrease of total Rac activation in PC-3 cells treated with 100ng/mL CCL2. Rescue experiments were performed by
introducing a siRNA-insensitive RhoG GTPase. Shown are means ± S.D. of at least triplicate analysis representing individual transfections,
with signiﬁcance being P<. 001; (∗) signiﬁes a signiﬁcant diﬀerence between siRNA-transfected cells and stimulated controls, while (∧)
signiﬁes a signiﬁcant diﬀerence between siRNA-transfected and -rescued cells.
across a BMEC layer in untransfected (UT) and siScr control
cells compared to untreated/untransfected cells (UN/UT).
Contrarytowhatweobservedforunstimulateddiapedesisin
Figure 1(c), there was an approximate 45% decrease in PC-3
diapedesis across the endothelial cell layer when RhoG was
depleted using siRNAs (P<. 001). Similarly, direct depletion
of Rac1 or treatment with the inhibitor NSC23766 led to
a signiﬁcant decrease in transendothelial cell migration.Journal of Signal Transduction 7
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Figure 3: Interaction of prostate cancer cells with bone marrow endothelial cells BMECs was attached to the AFM tip and the unbinding
forces of PCa cells measured. PC-3 cells were transfected with siRNAs speciﬁc for individual Rac isoforms. Shown are the results from one
set of siRNAs. (a) Eﬀect on the frequency of unbinding events and forces (pN) occurring between BMECs and PC-3 cells after depletion of
each Rac isoform. (b) Average unbinding force occurring between BMECs and PC-3 cells. The average unbinding force is the physical force
required to pull twoadhered cells apart.Data are compiledfrom 3000data points andarethe mean ± S.D.with signiﬁcancebeing ∗P<. 001.
Introduction of a siRNA-resistant RhoG fully rescued CCL2-
induced diapedesis in RhoG-depleted cells. However, intro-
duction of a RhoGQ63L fast cycling mutant did not rescue
the cells ability to cross an endothelial cell layer when Rac1
was depleted. Finally, Supplemental Figure 2(c) demon-
strates that CCL-2-induced diapedesis is inhibited in C4-2
cellswhen RhoGisdepleted.Again,introduction ofasiRNA-
resistant RhoG fully restores the cells ability to cross the
BMEC layer.
Figure 2(b) demonstrates that CCL2-induced total Rac
activation is decreased by ∼40% when RhoG is depleted
from the PC-3 cells, suggesting that CCL2 may activate
Rac1 directly and also indirectly through RhoG GTPase.
Concordant to what is observed in the diapedesis assay,
introduction of a siRNA-resistant RhoG restores actives
levels of total Rac similar to controls. Restoration of Rac
activity and PCa diapedesis in the rescue experiments were
not due to overexpression of nonphysiologic levelsof ectopic
RhoG. As shown in Figure 2(c), during rescue, mRNA levels
of RhoG were increased 4-fold over the RhoG-depleted
cells. These expression levels were still well under what is
observed for the siScr control cells. Similar results were
observed for the C4-2 cells and in the RNAi-insensitive Rac1
rescued cells. On average, an ∼70% transfection eﬃciency
was observed for each construct in both the PC-3 and C4-2
cells.
3.3. Rac1 GTPase Mediates the Interaction between PC-3 Cells
and BMECs. We previously demonstrated that downregula-
tion of Rac1 does not signiﬁcantly aﬀect PC-3 cell binding
to BMECs [18]. However, anecdotal evidence suggested that
Rac1depletionleadstodecreasedbindingstrengthofthePC-
3 cells to BMECs. To quantitate binding strength, we used
atomic force microscopy (AFM) to measure the unbinding
force of PC-3 cells bound to BMECs after Rac1, Rac3, or
RhoG depletion. For the siScr control, siRac3- and siRhoG-
treated PC-3 cells, a number of individual unbinding events
occurred over time (Figure 3(a)) suggesting tight binding of
multiple adhesion molecules is involved in cell-cell contact.
In contrast, down-regulation of Rac1 led to a signiﬁcant
decrease in the number and frequency of unbinding events
that occurred, suggesting fewer and weaker cell-cell contacts.
Figure 3(b) shows that depletion of Rac1 led to a signiﬁcant
average 85% decrease in the unbinding force of the PCa
cells to the bone marrow endothelial cells. Interestingly,
downregulationofRhoGdidnotaﬀecttheabilityofthePC-3
cells to bind to the BMECs, suggesting that RhoG activation
of Rac1 is not involved in cell-cell binding.
In a system resembling initial contact during diapedesis,
PC-3 cells were allowed to bind to a BMEC monolayer, and
the dynamic elastic modulus (a.k.a. Young’s modulus) was
measured using AFM. Because of the pronounced eﬀect of
Rac1 depletion on PCa cell adhesion to BMECs seen in
Figure 3, we compared siScr control and siRac1-transfected
PC-3 cells. Figure 4(a) shows that the elasticity was essen-
tiallyunchangedforthesiRNA-scrambledcontrolandsiRac1
PC-3 cells alone. Compared to the unbound cells, the siRNA
control PC-3 cells became more elastic (a decrease in the
Young’s modulus) when bound to BMECs suggesting that
they begin to spread onto the endothelial cell monolayer. In
contrast, the PC-3 cells transfected with siRNA to Rac1 were
signiﬁcantly less elastic (increase in the Young’s modulus)
than the unbound PC-3 cells when bound to BMECs
suggesting that they remain in a rounded conﬁguration
as we previously reported [16]. Figure 4(b) compares the
elasticity of the cells in the BMEC monolayer when engaged8 Journal of Signal Transduction
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Figure 4: Bone marrow endothelial cells react to PCa cell binding. (a, b) are measurements of the dynamic elastic modulus or elasticity
of PC-3 and BMECs in contact with one another. Elasticity is given as the Young’s modulus and is a ratio of cell stress and strain and is
measured in Pascals. BMECs were grown as a monolayer and control (siScr) or siRac1 expressing PC-3 cells were allowed to bind to the
BMEC monolayer, and the elasticity of the PC-3 cells (a) and the BMECs (b) was measured by AFM. Data are the result of over 10,000
data points and represented as mean ± S.D. with signiﬁcance being ∗P<. 001. (c) are measurements of transendothelial electrical resistance
(TEER). BMECs were grown on a monolayer, PC-3 cells were added to the monolayer, and the electrical resistance was measured every
10min up to 1h (i) and the ﬁnal measurement at 24h (ii).
by the PC-3 cells. BMECs had a signiﬁcant 30% increase in
elasticity when in contact with control PC-3 cells suggesting
reorganization of the actin cytoskeleton. In contrast, the
BMECs had no change in theirdynamic elastic modulus
when bound to Rac1-depleted PC-3 cells.
In a variation of this experiment, we allowed individual
BMECs to come into contact with a PC-3 cell monolayer
(Supplemental Figure 3). Again, the elasticity of the PC-3
cells was essentially unchanged due to downregulation of
Rac1. There was a signiﬁcant and consistent 30% increase inJournal of Signal Transduction 9
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Figure 5: Eﬀect of Rac1 GTPase on β1 integrin activation. (a) Comparison of total, partially and fully activated β1 integrinsin control and
Rac1 depleted PC-3 cells as assessedby FACS analysis.Cells were transfected witheither siRNA-scrambled controlor Rac1 siRNA(2) and left
unstimulatedortreated with100ng/mL CCL2.FACS analysiswasperformed after incubating ﬁxed cells with theantibodies MAR4 (fortotal
β1 integrin), N29 (for partially active β1 integrin), and HUTS21 (for fully active β1 integrin). (b) is a rescue experiment demonstrating that
introduction of either anRNAi-insensitive Rac1 or RhoG GTPase leads to restoration of active β1 integrin levels in CCL2-treated PC-3 cells.
Shown are the results of triplicate experiments showing the percentages of 10,000 gated events with signiﬁcance being ∗P<. 001. Capped
lines signify a comparison and signiﬁcance between siRNA-depleted cells and cells rescued with siRNA-insensitive constructs.
elasticity of the BMECs when they came in contact with the
controlPC-3 cells. However,therewas nochange in elasticity
of the BMECs when they came into contact with PC-3 cells
that had depleted Rac1.
Figure 4(c)(i) demonstrates a marked change in transen-
dothelial electrical resistance (TEER) across the BMEC layer.
TEER is a measure of the integrity oftight junctions between
cells. Decreased TEER is indicative of cellular retraction.
Addition of PC-3 cells to a conﬂuent BMEC layer led to a
signiﬁcant, time-dependent decrease in TEER. TEER levels
were fully restored, in a time-dependent manner by 24h
(Figure 4(c)(ii)). Taken together these data suggest that the
BMECs undergo cytoskeletal changes that inﬂuence their
elasticity when they interact with PC-3 cells.
3.4. Active Rac1 GTPase Leads to Stimulation of β1 Integrins.
Active Rho GTPases are known to lead to expression and
activation of integrins [36]. Two integrin heterodimers
are associated with binding to VCAM-1 and ICAM-1 on
endothelial cells, α4β1a n dαLβ2, respectively. With this in
mind, we set out to determine if Rac1 GTPase inﬂuenced
the activation state of integrins leading to BMEC binding.
Since β2 integrins are not associated with prostate cancer
and the role of the β1 integrins is established in PCa/BMEC
interactions [6, 8, 9], we focused on the expression and
activationoftheβ1 subunits.To determinethisﬂuorescence-
activated cell sorting (FACS), analysis was performed using
a set of antibodies that recognize total and active levels of
the β1 subunit. The MAR4 antibody recognizes total β1
integrin subunit regardless of activation state. The α4β1
heterodimer can exist in 3 conformations, closed head-
piece/bent (inactive), closed headpiece/extended (partially
activated, recognized by the N29 antibody), and open
headpiece/extended (fully active, recognized by the HUTS21
antibody). Figure 5(a) demonstrates that unstimulated PC-
3 cells have similar levels of total and partially activated β1
integrin as compared to Rac1-depleted PC-3 cells. When
the cells were treated with CCL2, thus leading to increased
Rac1 activation, there was no change in total and partially
activated levels of β1 integrin. However, signiﬁcantly more
fully activated β1 integrin was detected in the controlbutnot
Rac1-depleted PC-3 cells. For simplicity, the results shown
are from one siRNA; however, near identical results were
obtained with alternate siRNAs.
Figure 5(b) demonstrates that the decrease in CCL2-
stimulated β1 integrin activity due to Rac1 depletion can be
rescued by expression of an RNAi-insensitive Rac1 GTPase.
Similarly, depletion of RhoG GTPase led to a signiﬁcant
decrease in CCL2-induced active β1 integrin expression as
compared to scrambled control. Expression of a siRNA-
resistant RhoG led to a signiﬁcant increase in β1i n t e g r i n
activation. In both cases, the RNAi-insensitive GTPases
restored CCL2 activation of β1 integrin to levels comparable
to the control cells.
4.Discussion
The Rho GTPases comprise a subfamily of the Ras super-
family of monomeric GTP-binding proteins [21]. Like Ras,
the Rho proteins transiently move from an inactive to active10 Journal of Signal Transduction
to an inactive state via the GTPase cycle. This cycle is
controlled by a number of regulatory proteins, which in turn
r e g u l a t eR h os i g n a lt r a n s d u c t i o nv i ae ﬀector proteins [37–
41]. This coordinate regulation of the Rho proteins allows
for cytoskeletal reorganization leading to changes in cell
shape and motility [12, 42]. Overexpression and/or aberrant
activation of individual Rho GTPases has been shown in
a number of cancers and is thought to drive metastatic
progression [15]. Although one Rho protein may be the
predominant GTPase in a cancer, other GTPases must also
become active to reorganize the actin cytoskeleton and drive
migration.
RhoC GTPase is expressed in several cancers and pro-
motes metastasis [43–52]. Previously, we demonstrated that
RhoC GTPase expression and activation is required for PCa
invasion [16, 18–20]. When RhoC expression or activation is
downregulated, the PCa cells undergo Rac GTPase-mediated
EMT [16, 18]. Decreased Rho expression or activity leads
to increased expression and sustained activity of Rac1.
Furthermore, Rac expression and activation was found to
be required for tumor cell diapedesis across a human BMEC
layer. We believe that together RhoC and Rac are needed to
drive PCa extravasation from the vasculature into the bone
marrow environment.
There are four members of the Rac branch of the Rho
subfamily: Rac1, Rac2, Rac3, and RhoG. Rac1 and Rac3, but
not Rac2, are shown to have increased expression in PCa,
while expression ofRhoG hasnot beenexamined [33].Inthe
current study, we set out to determine the individual roles of
Rac1, Rac3, and RhoG in tumor cell diapedesis. Rac1 levels
are signiﬁcantly higher than either Rac3 or RhoG suggesting
that it is the predominant Rac GTPase in these cells. The
relative levels of Rac1 and Rac3 in PCa are similar to what
has been shown in glioblastoma cells [26].
Rac3 GTPase has clearly been shown to be involved in
adhesion of tumor and normal cells of neural origin [24,
26]. Normal and malignant prostate has a neuroendocrine
component; therefore, the question arises if Rac3 expression
plays a role in neuroendocrine diﬀerentiation of PCa [53–
55]. We have clear AFM data that implicates Rac3 in binding
of PCa cells to ﬁbronectin and to a lesser extent, collagen
I (unpublished data). Binding to laminin would be the
next logical choice to examine. This aspect may also begin
to explain the apposing eﬀect that Rac3 has on Rac1 and
transendothelial cell migration. We found that downreg-
ulation of Rac3 led to an increase in total Rac activity,
independent of an increase in total Rac protein levels. A
similar observation was made previously; downregulation of
RhoC increased Rac1 activity [16, 18]. However, this was
accompanied by an increase in total Rac1 protein.
Expression of RhoG is found ubiquitously throughout
the body, but its expression in PCa has not been studied.
We found that RhoG, although expressed in low levels, has
an eﬀect on total Rac activation. Inhibition of RhoG led
to a signiﬁcant decrease in Rac activation, but diapedesis
was slightly increased. In contrast, CCL2-stimulation of
PCa cells transfected with siRNA speciﬁc for RhoG sig-
niﬁcantly decreased diapedesis. Coexpression of a siRNA-
resistant RhoG led to restoration of the cells ability to
cross the endothelial cell layer. Furthermore, depletion of
RhoG led to a signiﬁcant decrease in CCL2-stimulated Rac
activation, suggesting that CCL2 activates Rac1. Expression
of a fast cycling RhoG in Rac1-depleted cells did not rescue
the cells ability to undergo diapedesis. This also suggests
that Rac1-mediated diapedesis may be regulated through
direct activation of Rac1 or indirectly via RhoG GTPase
and the diﬀerent eﬀects that RhoG has on PCa diapedesisis
intriguing. Without CCL2 stimulation, RhoG appears to act
like Rac3 and limit diapedesis, even after decreasing total
Rac activation. Upon CCL2 stimulation, RhoG appears to
play a role in activating Rac1 thereby decreasing diapedesis.
This may suggest a speciﬁc RhoG GEF(s) that are activated
by CCL2. Also of interest is the fact that ectopic expression
of an RNAi-insensitive RhoG led to a signiﬁcant decrease
in unstimulated diapedesis suggesting a balance of RhoG
expression required for migration.
Ourresultsmeasuring BMECstiﬀnessusingAFMshowed
speciﬁc diﬀerences that were consistent over a large array
of experimental attempts suggesting a speciﬁc biological
interaction. The PC-3/BMEC interaction is of particular
interest; PC-3 cells, whether adhered to substrate or attached
to a BMEC, maintain a constant measured elastic modulus.
T h eB M E C s ,h o w e v e r ,w h e ni nc o n t a c tw i t haP C ac e l l
consistently, undergo a 30% decrease in stiﬀness. This
apparent conferred decrease in stiﬀness points to a change in
theinternalcytoskeletalarchitecture oftheBMEC.Depletion
of Rac1 in the PC-3 cells led to a signiﬁcant decrease in
the strength of binding to the BMECs. The elasticity of
the BMEC cell was not decreased when bound to a Rac1-
depleted PC-3 cell indicating a Rac1-mediated interaction
between the two cells. This interaction may be due, at
least in part, to binding mediated by β1 integrins. We
demonstrate that unstimulated PC-3 cells have partially
activatedβ1integrins thatbecomefullyactivateduponCCL2
stimulation and activation of Rac1. Clearly, β1 integrins are
required for binding of PCa cells to extracellular matrix
[7, 19, 20, 56, 57]. Studies in the literature suggest a role
for β1 integrins in binding PCa to BMECs [6, 7, 58, 59].
One report suggests that the use of a β1 integrin-blocking
antibody did not aﬀect PC-3 cell binding to the human bone
marrow endothelialcelllineHBME-1butwasresponsiblefor
mediating PCa interactions with ﬁbronectin [7]. However,
other studies show a role for β1 integrins in binding to
other bone marrow endothelial cells [58, 59]. Rho GTPases
such as Rac1 are implicated in bidirectional signaling with
integrins activating Rho proteins and the active Rho proteins
promoting integrin dimer activation increasing binding
strength [36, 60, 61].
These mechanisms are similar to leukocyte diapedesis,
where, after initial binding, the interaction between the
leukocyte and endothelial cell increases leading to dynamic
cytoskeletal changes and endothelial cell retraction [62, 63].
Although this has been suggested for PCa diapedesis, this is
theﬁrst timethishasbeenshown experimentally. Acomplete
understanding of how these diﬀerent Rac proteins are
activated and how they contribute to tumor cell diapedesis
may have profound implications for any strategies targeting
the extravasation process.Journal of Signal Transduction 11
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